1st Quarter - Report

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Firm
Client
Income
—
Expenses
$800,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Education related to Hepatitis C. Access to Care Act, HR 4810

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: H.R. 4810 (114th)

Health Issues HCR

Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization, Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. HIV/AIDS testing and treatment, technology transfer and patent rights, and funding. Patient Protection and Affordable Care Act implementation. Hepatitis funding for screening and linkage to care programs.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
ARANTHAN STEVE JONES, II New Health Policy Advisor, Senior Health Policy Advisor, Health Policy Director, Deputy Chief of Staff & Senior Advisor, Chief if Staff, Chieft of Staff and Senior Policy Advisor, Director Policy and Researvch, Policy Director, House of Representatives.
DAVID PULLIAM —

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
ARANTHAN STEVE JONES, II New Health Policy Advisor, Senior Health Policy Advisor, Health Policy Director, Deputy Chief of Staff & Senior Advisor, Chief if Staff, Chieft of Staff and Senior Policy Advisor, Director Policy and Researvch, Policy Director, House of Representatives.
DAVID PULLIAM —

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

International Trade and protection of intellectual property; HIV policy Issues, HCV issues, Patent Reform.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Defense DEF

Education related to HCV issues.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
DAVID PULLIAM —

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

HIV/AIDS testing and treatment, technology transfer and patent rights and funding. Patient Protection and Affordable Care Act implementation.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
ARANTHAN STEVE JONES, II New Health Policy Advisor, Senior Health Policy Advisor, Health Policy Director, Deputy Chief of Staff & Senior Advisor, Chief if Staff, Chieft of Staff and Senior Policy Advisor, Director Policy and Researvch, Policy Director, House of Representatives.
DAVID PULLIAM —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.